All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher the proportion of participants with self‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change in quality of life · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher proportion of participants with investigator‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline to study conclusion in total hair count · women with FPHL
1 finding from 1 review
Degree of hair shedding from baseline to the end of the study · women with FPHL
1 finding from 1 review
Cosmetic appearance of the hair or participant satisfaction · women with FPHL
1 finding from 1 review
Change in quality (or pattern) of hair regrowth (e.g. thickness) · women with FPHL
1 finding from 1 review
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
Thromboembolism · People with a haematological disorder
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes death from any cause compared with standard regimen alone (very low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes TB‐related death compared with standard regimen alone (very low certainty).
1 finding from 1 review